American Shared Hospital Services (AMS) स्टॉक विश्लेषण

कंपनी का अवलोकन

American Shared Hospital Services (AMS) operates within the healthcare sector, specifically providing technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services. The company functions through two distinct segments, Leasing and Retail, where it leases nine Gamma Knife systems alongside one proton beam radiation therapy (PBRT) system to medical facilities. As of the latest data, the firm maintains a market capitalization of $8.78M and generates annual revenue of $28.08M, while the specific employee count remains unlisted in available records. This modest market valuation combined with a single-digit revenue figure suggests the company occupies a niche position within the broader medical care facilities industry rather than holding a dominant market share. The scale of operations, indicated by the limited number of leased high-value systems, reflects a specialized business model focused on capital-intensive medical equipment rather than large-scale volume manufacturing or service provision.

वित्तीय स्वास्थ्य

The company reports a trailing twelve-month revenue of $28.08M against a net income loss of $1.553M, and an EBITDA of $3.70M, revealing a significant gap between operational earnings before interest and taxes and the final bottom line. This disparity between EBITDA and net income indicates a substantial cost structure burdened by interest expenses, taxes, or depreciation costs that consume nearly half of the operating earnings. The free cash flow stands at a negative $3.9955M, which implies that the company is currently burning cash and lacks the immediate liquidity to fund expansion without external financing. Furthermore, the balance sheet shows a cash balance of $3.46M offset against a total debt obligation of $21.67M, resulting in a debt-to-equity ratio of 78.27, which characterizes the firm as highly leveraged rather than conservative. The current ratio of 0.76 signals that the company's current liabilities exceed its current assets, indicating potential challenges in meeting short-term obligations. Additionally, the return on equity is negative at -9.4% and the return on assets is -2.2%, demonstrating that management effectiveness has resulted in value destruction rather than wealth generation for shareholders over the trailing period.

मूल्यांकन आकलन

The valuation metrics present a complex picture with a trailing P/E ratio listed as N/A due to negative earnings, while the forward P/E is calculated at 3.33, suggesting a market expectation of future profitability despite current losses. The price-to-book ratio sits at 0.36, indicating that the stock trades at a significant discount to its tangible book value, which often occurs in distressed or turnaround situations. Alternative valuation measures like the price-to-sales ratio of 0.31 and an EV/EBITDA of 8.28 provide context that the market is pricing the company based on sales multiples rather than earnings potential. The stock has traded between a 52-week high of $3.11 and a 52-week low of $1.29, placing the current market price in a volatile range that reflects uncertainty about the company's recovery trajectory. The beta value of 0.29 suggests that the stock exhibits low price volatility relative to the broader market, moving significantly less than the overall index during periods of market stress.

Growth & Income

Revenue growth for the year-over-year period shows a decline of -14.8%, while earnings growth is marked as N/A due to the negative net income position. The contraction in revenue is evident, and since earnings are negative, the relationship between earnings and revenue growth rates cannot be directly compared in traditional terms, but the revenue decline clearly points to shrinking top-line performance. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning it reinvests all available resources or retains cash to manage its heavy debt load rather than distributing income to shareholders. The overall growth and income profile is currently constrained by a shrinking revenue base and a complete absence of dividend income, positioning the stock purely as a speculative vehicle rather than an income or steady growth investment.